| __timestamp | CymaBay Therapeutics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 7459000 |
| Thursday, January 1, 2015 | 17026000 | 11831000 |
| Friday, January 1, 2016 | 15941000 | 25705000 |
| Sunday, January 1, 2017 | 18938000 | 46181000 |
| Monday, January 1, 2018 | 58124000 | 59497000 |
| Tuesday, January 1, 2019 | 83837000 | 65003000 |
| Wednesday, January 1, 2020 | 35882000 | 74506000 |
| Friday, January 1, 2021 | 64542000 | 126006000 |
| Saturday, January 1, 2022 | 67995000 | 126215000 |
| Sunday, January 1, 2023 | 80118000 | 120161000 |
Unlocking the unknown
In the ever-evolving world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CymaBay Therapeutics, Inc. and Protagonist Therapeutics, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical breakthroughs.
From 2014 to 2023, CymaBay Therapeutics increased its R&D expenses by over 400%, peaking in 2023. This upward trend underscores the company's strategic focus on expanding its therapeutic pipeline.
Similarly, Protagonist Therapeutics exhibited a remarkable growth trajectory, with R&D spending surging by approximately 1,500% during the same period. Notably, their investment in 2022 was nearly double that of 2017, highlighting a robust commitment to innovation.
These trends not only reflect the companies' growth but also their pivotal role in shaping the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
Comparing Innovation Spending: Sanofi and CymaBay Therapeutics, Inc.
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Protagonist Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development Expenses Breakdown: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending